TELA Bio Taps Turnaround Titans for Board in Bold Push for Profitability

MALVERN, PA – April 30, 2026 – TELA Bio, Inc. today executed a bold strategic pivot, announcing a sweeping board refreshment that installs four highly experienced commercial and financial leaders, a move clearly designed to accelerate the medtech company's long-sought path to profitability. The announcement of the new board, packed with turnaround specialists and dealmakers, was coupled with preliminary first-quarter revenues that surpassed the company's own guidance, painting a picture of a company in transition, eager to leverage its clinical innovations into financial success.

In a decisive maneuver, the commercial-stage company focused on soft-tissue reconstruction will replace four of its seven directors, including its Chairman, with a new slate of executives renowned for scaling medtech companies and delivering substantial shareholder value through strategic acquisitions and operational overhauls. The move signals a clear shift in focus from foundational growth to aggressive commercial execution and financial discipline.

A New Guard for a New Phase

The board refreshment, described as a unanimous decision, will see Chairman Doug Evans and directors Kurt Azarbarzin, Vince Burgess, and Federica O’Brien step down following the company's annual stockholder meeting on June 9, 2026. The company was clear that the departures were amicable and intended to make way for new expertise.

“We are extremely grateful to Doug, Vince, Kurt, and Freddi for their many contributions in building TELA Bio into a commercial-stage company with a strong foundation in soft-tissue reconstruction,” said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio, who will remain on the board. “This is a pivotal step forward for the Company.”

Taking their places is a quartet of industry veterans whose collective resume reads like a who's who of medtech value creation. Joseph Capper, the current CEO of MiMedx Group, is set to become the new Chairman. He is joined by Guido Neels, a former Guidant COO and current partner at EW Healthcare Partners; Guy Nohra, a co-founder of venture capital firm Alta Partners; and Paul Thomas, a serial CEO who led LifeCell Corporation to a $1.8 billion acquisition.

The new directors’ expertise directly aligns with TELA Bio’s pressing need to translate its growing sales into a sustainable business model. The company has demonstrated impressive top-line growth with its OviTex® line of reinforced tissue matrices, but profitability has remained elusive.

The Turnaround Playbook

The backgrounds of the incoming directors provide a clear roadmap of the board’s new mandate: profitability and shareholder return. Each new member brings a history of significant financial success and strategic exits.

• Joseph Capper, the incoming Chair, is best known for his dramatic turnaround of BioTelemetry, Inc. He took the helm in 2010 and guided the company from significant challenges to a blockbuster $2.8 billion acquisition by Royal Philips in 2021. His track record in executing turnarounds and creating substantial value is precisely the kind of leadership investors look for in a company at an inflection point.

• Paul Thomas offers a similar narrative. As CEO of LifeCell Corporation, he steered the regenerative medicine company to a $1.8 billion sale to KCI, a landmark deal in the sector. His experience demonstrates a keen ability to build a company with innovative technology and position it for a highly successful strategic exit.

• Guido Neels brings deep operational and commercialization expertise from his time as Chief Operating Officer of Guidant Corporation, a cardiovascular leader acquired for $25 billion. His experience managing global sales, marketing, and corporate strategy for a medtech giant provides TELA Bio with invaluable insight into scaling its commercial operations effectively.

• Guy Nohra, a venture capitalist named to the Forbes “Midas List,” adds a crucial investor perspective. As a co-founder of Alta Partners, he has been instrumental in funding and developing numerous successful medtech and life science companies, giving him a sharp eye for market opportunities and the strategies required to capitalize on them.

From Innovation to Commercialization

This strategic overhaul reflects a broader trend in the medical device industry, where clinical innovation alone is no longer sufficient for success. In the highly competitive soft-tissue reconstruction market, estimated to be worth over $15 billion, TELA Bio competes against giants like Johnson & Johnson, Stryker, and Medtronic. While TELA Bio has successfully carved out a niche with its technology that prioritizes the patient’s own anatomy, the next phase requires a different skill set.

The company has posted strong revenue growth for years, including a period of eleven consecutive quarters with over 35% year-over-year growth. However, this has been accompanied by persistent net losses, with the company reporting a net loss of $11.0 million in the third quarter of 2023. This financial reality has put pressure on the company's valuation and led to a Nasdaq bid-price deficiency notice.

The board refreshment is a direct answer to this challenge. It signals a maturation from a research-and-development-focused entity to a commercially-driven enterprise laser-focused on market penetration, operational efficiency, and, ultimately, the bottom line.

A Signal of Strength or a Response to Pressure?

The timing of the announcement, paired with better-than-expected preliminary revenue, is strategically astute. The company reported preliminary Q1 2026 revenue of approximately $19.0 million, beating its guidance of $18.5 million. This provides a positive backdrop for the leadership transition and suggests the company’s underlying commercial efforts are gaining traction.

However, the move can also be interpreted as a response to mounting pressure. Despite a consensus price target from analysts that suggests significant upside, the stock has underperformed, and an increase in short interest indicates some investor skepticism. The board overhaul is a powerful statement to the market that the company is taking decisive action to address these concerns.

The infusion of leadership known for financial discipline and successful M&A outcomes is a clear signal that all strategic options are on the table. While the immediate goal is to drive the company toward profitability, the new board's collective experience in orchestrating strategic acquisitions will not be lost on investors. The company's full financial results, scheduled for release on May 12, will offer the first deep look into the company's performance and provide further context for this pivotal strategic shift.